The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Molecular and clinical features of pancreatic acinar cell carcinoma: A single institutional experience.
 
Ashwathy Balachandran Pillai
No Relationships to Disclose
 
Mahmoud M.G. Yousef
No Relationships to Disclose
 
Abdelrahman M.G. Yousef
Other Relationship - Palantir Technologies
 
Mark W. Hurd
No Relationships to Disclose
 
Huamin Wang
No Relationships to Disclose
 
Anirban Maitra
Consulting or Advisory Role - Freenome; Tezcat Biosciences
Patents, Royalties, Other Intellectual Property - Johns Hopkins University has licensed a patent related to pancreatic cancer to Thrive Earlier Detection. I have 1.8% contribution on that patent.; PCT/US2017/066851 (Inst)
 
Jason Willis
Honoraria - Bayer; Cor2Ed
Consulting or Advisory Role - Healios, K.K.
 
John Paul Y.C. Shen
Stock and Other Ownership Interests - Agios; Syndax; Syndax
Consulting or Advisory Role - Engine Biosciences; NaDeNo Nanosciences
Research Funding - BostonGene; Celsius Therapeutics; Celsius Therapeutics
 
Shubham Pant
Consulting or Advisory Role - Alligator Bioscience; AskGene Pharma; AstraZeneca; Boehringer Ingelheim; BPGbio; Ipsen; Janssen; Jazz Pharmaceuticals; Nihon Medi-Physics; Novartis; US WorldMeds; Zymeworks
Research Funding - 4D Pharma (Inst); Amal Therapeutics (Inst); Arcus Biosciences (Inst); Astellas Pharma (Inst); bionte (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Elicio Therapeutics (Inst); Immuneering (Inst); ImmunoMET (Inst); Ipsen (Inst); Janssen (Inst); Lilly (Inst); Mirati Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Novartis (Inst); Pfizer (Inst); Purple Biotech (Inst); Rgenix (Inst); Xencor (Inst); Zymeworks (Inst)
 
Brandon George Smaglo
Consulting or Advisory Role - Ipsen; Syros Pharmaceuticals
Research Funding - AstraZeneca; Merck
Travel, Accommodations, Expenses - Marker Therapeutics
(OPTIONAL) Uncompensated Relationships - Ipsen
 
Robert A. Wolff
Honoraria - Conveners; Emirates Oncology Society
Patents, Royalties, Other Intellectual Property - Royalties from McGraw-Hill: Editor: M.D. Anderson Manual of Medical Oncology, 3rd edition.
 
Dan Zhao
Consulting or Advisory Role - Affinit-T
Research Funding - CARsgen Therapeutics (Inst); Mirati Therapeutics (Inst); TriSalus Life Sciences (Inst)